NCT00435669View on ClinicalTrials.gov

A Phase I Study to Determine Absorption, Distribution, Metabolism, and Elimination of a Single Radiolabeled Dose of Brivanib (BMS-582664)

PHASE1CompletedINTERVENTIONAL
Enrollment

4

Participants

Timeline

Start Date

September 30, 2007

Primary Completion Date

June 30, 2008

Study Completion Date

June 30, 2008

Conditions
Tumors
Interventions
DRUG

Brivanib

Oral Solution, Oral, 800 mg, X1 on Day 1, 10 D for ADME

DRUG

Brivanib

Tablet, Oral, Brivanib 800 mg, QD, until progression

Trial Locations (1)

44195

Cleveland Clinic Foundation, Cleveland

Sponsors
All Listed Sponsors
lead

Bristol-Myers Squibb

INDUSTRY